Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

Wendy P. Bannister, Lidia Ruiz, Alessandro Cozzi-Lepri, Amanda Mocroft, Ole Kirk, Schlomo Staszewski, Clive Loveday, Anders Karlsson, Antonella D Arminio Monforte, Bonaventura Clotet, Jens D. Lundgren, M. Losso, A. Duran, N. Vetter, I. Karpov, A. Vassilenko, N. Clumeck, S. DeWit, B. Poll, R. ColebundersK. Kostov, J. Begovac, M. Ristola, L. Machala, H. Rozsypal, D. Sedlacek, J. Nielsen, J. Lundgren, T. Benfield, O. Kirk, J. Gerstoft, T. Katzenstein, A. B E Hansen, P. Skinhøj, C. Pedersen, L. Oestergaard, K. Zilmer, J. Smidt, C. Katlama, J. P. Viard, P. M. Girard, J. M. Livrozet, P. Vanhems, C. Pradier, F. Dabis, J. Rockstroh, R. Schmidt, J. Van Lunzen, O. Degen, H. J. Stellbrink, S. Staszewski, J. Bogner, G. Fätkenheuer, J. Kosmidis, P. Gargalianos, G. Xylomenos, J. Perdios, G. Panos, A. Filandras, E. Karabatsaki, H. Sambattakou, D. Banhegyi, F. Mulcahy, I. Yust, D. Turner, M. Burke, S. Pollack, G. Hassoun, S. Maayan, A. Chiesi, R. Esposito, I. Mazeu, C. Mussini, C. Arici, R. Pristera, F. Mazzotta, A. Gabbuti, V. Vullo, M. Lichtner, A. Chirianni, E. Montesarchio, M. Gargiulo, G. Antonucci, F. Iacomi, P. Narciso, C. Vlassi, M. Zaccarelli, A. Lazzarin, R. Finazzi, M. Galli, A. Ridolfo, A. D'Arminio Monforte, B. Rozentale, P. Aldins, S. Chaplinskas, R. Hemmer, T. Staub, P. Reiss, J. Bruun, A. Maeland, V. Ormaasen, B. Knysz, J. Gasiorowski, A. Horban, D. Prokopowicz, A. Wiercinska-Drapalo, A. Boron-Kaczmarska, M. Pynka, M. Beniowski, E. Mularska, H. Trocha, F. Antunes, E. Valadas, K. Mansinho, F. Maltez, D. Duiculescu, A. Rakhmanova, E. Vinogradova, S. Buzunova, D. Jevtovic, M. Mokráš, D. Staneková, J. González-Lahoz, V. Soriano, L. Martin-Carbonero, P. Labarga, B. Clotet, A. Jou, J. Conejero, C. Tural, J. M. Gatell, J. M. Miró, P. Domingo, M. Gutierrez, G. Mateo, M. A. Sambeat, A. Karlsson, P. O. Persson, L. Flamholc, B. Ledergerber, R. Weber, P. Francioli, M. Cavassini, B. Hirschel, E. Boffi, H. Furrer, M. Battegay, L. Elzi, E. Kravchenko, N. Chentsova, S. Barton, A. M. Johnson, D. Mercey, A. Phillips, M. A. Johnson, A. Mocroft, M. Murphy, J. Weber, G. Scullard, M. Fisher, R. Brettle, B. Clotet, F. Antunes, B. Clotet, D. Duiculescu, J. Gatell, B. Gazzard, A. Horban, A. Karlsson, C. Katlama, B. Ledergerber, A. D'Arminio Montforte, A. Phillips, A. Rakhmanova, P. Reiss, J. Rockstroh, J. Lundgren, O. Kirk, A. Mocroft, N. Friis-Moller, A. Cozzi-Lepri, W. Bannister, M. Ellefson, A. Borch, D. Podlevkareva, C. Holkmann Olsen, J. Kjar, L. Peters, J. Reekie

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To compare virological outcome and genotypic resistance profiles in HIV-1-infected patients starting non-nucleoside reverse transcriptase inhibitor (NNRTI)-containing regimens. METHODS: NNRTI-naive patients were included who started treatment with nevirapine (NVP) or efavirenz (EFV) with genotypic resistance test results available at time of initiation (baseline). Virological failure was defined as two consecutive values > 500 copies/ml after starting the regimen. Cox models were used to investigate time to virological failure (the first of two values). RESULTS: A total of 759 patients were included (13% antiretroviral-naive): 389 initiated NVP and 370 initiated EFV. Baseline IAS-USA NNRTI resistance mutations were detected in 3%. Using the Rega algorithm (version 7.1) to interpret resistance, 460 (64%) patients had resistance (full or intermediate) to at least one drug they were starting (69% NVP, 60% EFV, P = 0.011); 287 (74%) NVP and 168 (45%) EFV patients experienced virological failure after treatment initiation, P <0.001. After adjustment for previous antiretroviral use, previous AIDS, year started NNRTI, CD4 cell count (baseline, nadir), viral load (baseline, maximum), and baseline drug resistance (measured by Rega), the relative hazards (EFV versus NVP) of virological failure was 0.50, 95% confidence interval: 0.39-0.65, P <0.001. At time of virological failure, comparable levels of NNRTI resistance were detected. The K103N mutation emerged more in patients failing EFV and Y181C in patients failing NVP. CONCLUSIONS: NVP may be associated with an inferior virological outcome compared to EFV in NNRTI-naive patients with extensive resistance to other drug classes. The profile of NNRTI resistance mutations when virologically failing an NNRTI-containing regimen appears to depend on the NNRTI the patients fail.

Original languageEnglish
Pages (from-to)367-376
Number of pages10
JournalAIDS (London, England)
Volume22
Issue number3
DOIs
Publication statusPublished - Jan 2008

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA'. Together they form a unique fingerprint.

Cite this